Abstract 69P
Background
We aimed to evaluate the use of bevacizumab for patients with FIGO stage IIIB to IV advanced epithelial ovarian cancer (EOC) undergoing primary debulking surgery (PDS) in the primary disease setting using real-world data from a German cancer registry.
Methods
We identified patients with the initial diagnosis of FIGO stage IIIB to IV EOC, reported between 2009 and 2022 from the clinical cancer registry of Baden-Wuerttemberg, Germany. We excluded patients with recurrent disease, neoadjuvant chemotherapy, inoperable disease, or with insufficient information on systemic treatment or follow-up. The influence of Bevacizumab in addition to Carboplatin and Paclitaxel (Cb+T+Bev vs. Cb+T) on progression-free survival (PFS) and overall survival (OS) was assessed using Kaplan- Meier statistics and multivariate Cox regression models, adjusted for age, grading, stage, tumor histology, use of poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor, and PDS outcome (macroscopic complete gross resection, residual disease ≤1cm and >1cm).
Results
A total of 835 patients with a median follow-up of 25.1 months were identified: 542 patients (64.9%) had FIGO stage IIIB/C disease, 293 (35.1%) had FIGO stage IV disease. Post-operative residual disease was complete gross resection in 468 (56.0%), ≤1cm in 181 (21.7%), and >1cm in 186 (22.3%). Median age was 63.8 years (SD 11.1). Use of Cb+T+Bev was 40.1% (335/835) overall, 43.8% (205/468) for patients with complete gross resection, 38.7% (70/181) for patients with ≤1cm residual disease, and 32.3% (60/186) for patients with >1cm residual disease. Cb+T+Bev was not associated with improved OS (HR 0.88, 95% CI 0.73-1.07, P=0.216) or PFS (HR 0.95, 95% CI 0.79-1.10, P=0.610). Also in the subgroup of patients with >1cm residual disease, Cb+T+Bev was not associated with improved OS (HR 0.90, 95% CI 0.61-1.31, P=0.565) or PFS (HR 0.86, 95% CI 0.56-1.32, P=0.483).
Conclusions
This data suggests that bevacizumab is often used for patients with primary FIGO stage IIIB to IV EOC undergoing PDS although it does not provide an OS or PFS benefit.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.